Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

Hikma Pharmaceuticals PLC posted robust financial results for 2024, with revenue climbing 9% to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released Wednesday. The ...

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the ...

Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2024.

The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The AVPN Southeast Asia Summit 2025, held at Fairmont Singapore on 24 and 25 February, brought together over 450 investors, leading philanthropists, government officials, policymakers, and impact ...

BioCryst Pharmaceuticals stock climbs 9% on strong Orladeyo sales, 2025 revenue guidance boost, and market dominance. See why ...